Stemedica

TECHNOLOGY ADVANTAGE

Stemedica has developed eleven unique and proprietary stem cell lines known as StemedicaMCT™ (Stemedica Multiple Cell Technology). These products provide Stemedica with the ability to create multiple cell formulations in treating specific medical conditions or disease states, or to apply a single cell application for a specific treatment protocol.

Stemedica uses proprietary processes and procedures for manufacturing and Master Banking these adult stem cell lines. Technology advantages include:

  • Stem cells that are immune privileged - stem cell transplantation does not require immunosuppressant agents.
  • Quality control and safety monitoring and measurement protocols that follow FDA/cGMP guidelines including tumorgenicity and toxicity testing at FDA recognized laboratories.
  • Stem cells with proven reliability, potency and migratory properties.
  • Proprietary Master Banking processes that insure cell preservation and viability.
  • Proven protocols for stem cell transplantation.

MULTIPLE CELL LINES

Donor/Patient